All News

obesity.knee_.arthritis.jpg

Prevalence of Arthritis Rising in the USA

d MMWR

The latest CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million (23.7%) U.S. adults have arthritis, 25.7 million (43.9%) of whom have AAAL. 

Read Article
bouchard.JPG

Erosive Hand Osteoarthritis Portends Worse OA

d Jack Cush, MD

An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.

This was a longitudinal cohort study of 3,365 individuals without prevalent erosive hand OA at baseline.

Read Article
DAPSA PsA measure

Pathways to a Psoriatic Arthritis Diagnosis

d Jack Cush, MD

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different subspecialties.

Read Article
RA,hand,elderly,active

Malnutrition and Quality of Life in Elderly RA Patients

d Jack Cush, MD

Rheumatoid arthritis (RA) imparts a significant disabilty and quality of life (QoL) limitations worsened by aging, but also by malnutrition.

Read Article
Having both Cancer & Systemic sclerosis (SSc) is rare. Study of 1481 SSc pts saw cancer Dx w/in 2, (1.35), 3 (2.1%) & 5 yrs (3.5%;mostly breast, GYN, Heme CA). Higher 2 yr risk w/ topoisomerase I Ab (OR 3.43), U1-RNP (5.54), but not RNA polymerase III) https://t.co/dVuchv8Afv https://t.co/azGmJYifrj

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 52 pts with Juvenile Systemic Sclerosis (JSSc) -10% were without skin dz (SSc sine scleroderma). 7 pts reviewed, all had cardiac dz (86 vs 16%; 3 cardiomyopathy, 3PAH), longer Dx delay (20 vs 8 mos), worse outcomes, (42 v 6%) https://t.co/7wGuX8QVBO https://t.co/XdTK7AlPrs

Links:

Dr. John Cush RheumNow ( View Tweet)
MEDWATCH (FAERS) data on venous thromboembolic (VTE) risk with JAK inhibitors from 2010-2019 https://t.co/oKkTYcRsxL

Links:

Dr. John Cush RheumNow ( View Tweet)

“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/mJ467Nfe8T

Links:

Dr. John Cush RheumNow ( View Tweet)
Hip fractures represent a major global public health problem - data from ASBMR meeting suggests this is from an aging population and suboptimal OP treatment. Global study shows incr # hip fractures per year, but Post-fracture Rx only at 11-50% https://t.co/LlMDTrH93E https://t.co/ucrPzcnLZh

Links:

Dr. John Cush RheumNow ( View Tweet)
2125 RA pts in RCTS w/ baricitinib entered a long term F/U study. baricitinib pts had less XRay damage over 5 yrs; 5 yr No Xray progression was 60% on baricitinib 4 mg; 66% baricitinib 4 mg+MTX; vs 41% on just MTX monotherapy. https://t.co/pLuQCDSf6g https://t.co/wFs3G0DrJ7

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE hospitalized with ARDS from COVID-19 have significantly higher risks of death and poor outcomes (RR=1.7), compared 319 SLE vs 251,800 nonSLE - SLE was more impactful than other comorbidities in such poor outcomes https://t.co/8VJjdOmTbi https://t.co/jYTg6k1QNq

Links:

Dr. John Cush RheumNow ( View Tweet)
We are at that time of year when rheumatology fellowship programs across the nation are exploring potential candidates to train. We share tips for both the interviewer and candidates on the blog today. https://t.co/eWQs9CwqSm https://t.co/iHeuQpsoQx

Links:

Dr. John Cush RheumNow ( View Tweet)
Lessebo effect: 31 RCT comparing Biologic originator to a biosimilar or to PBO: Lessebo effx =better responses in Biosimilar vs PBO (ACR20=70%) than w/ originator vs PBO (ACR20=59%). ? due to PBO effx in active comparator, nocebo in PBO trials https://t.co/kvANomTHrb

Links:

Dr. John Cush RheumNow ( View Tweet)

Beliefs translate to effects - ‘it will work’ (Placebo), ‘it will hurt’ (Nocebo); but now a "Lessebo" effect; neither benefit nor harm; instead a lower effect based on comparator. TNFi vs PBO has smaller effx (sup trial) than Biosimilar vs PBO (equiv) https://t.co/onyIkILqT9

Links:

Dr. John Cush RheumNow ( View Tweet)

Drug Safety Risk Communication- The 800 lb Gorilla Approach https://t.co/6iSJjvlFF8 https://t.co/mPeJfWi1hY

Links:

Dr. John Cush RheumNow ( View Tweet)
ASK CUSH ANYTHING! Rheums: Have a question for Dr. Cush? Record it here and we may feature it on an upcoming podcast. #RheumNow https://t.co/wzNmOzH4VE https://t.co/KzPzWpSoW1

Links:

Dr. John Cush RheumNow ( View Tweet)
Metabolic syndrome (MetS) is associated with radiographic & nodal hand OA (HOA). 896 MetS positive & 1613 w/o MetS assessed w/ propensity matching. MetS had more xray HOA ((OR 1.32), PIPs (OR 1.52), DIPs (1.38), hand pain (1.25)https://t.co/aNEV5b6Tmv

Links:

Dr. John Cush RheumNow ( View Tweet)

Malnutrition and Quality of Life in Elderly RA Patients https://t.co/4hEFTSaCga https://t.co/OPK3ThWqst

Links:

Dr. John Cush RheumNow ( View Tweet)
Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found. Read more on #RheumNow https://t.co/jQt5mFrMtS https://t.co/HljgqdKZtH

Links:

Dr. John Cush RheumNow ( View Tweet)
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function. https://t.co/faLi0X840d https://t.co/8iZkNEFkRy

Links:

Dr. John Cush RheumNow ( View Tweet)
×